Immune checkpoint inhibitor

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Priming Immunotherapy in Advanced Disease With Radiation

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Biomarkers in Immunotherapy of Melanoma

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy

EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database